First Time Loading...

Iovance Biotherapeutics Inc
NASDAQ:IOVA

Watchlist Manager
Iovance Biotherapeutics Inc Logo
Iovance Biotherapeutics Inc
NASDAQ:IOVA
Watchlist
Price: 7.78 USD -4.42% Market Closed
Updated: Jun 8, 2024

Iovance Biotherapeutics Inc
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Iovance Biotherapeutics Inc
Income from Continuing Operations Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
Iovance Biotherapeutics Inc
NASDAQ:IOVA
Income from Continuing Operations
-$449.6m
CAGR 3-Years
-19%
CAGR 5-Years
-27%
CAGR 10-Years
-33%
Abbvie Inc
NYSE:ABBV
Income from Continuing Operations
$6B
CAGR 3-Years
5%
CAGR 5-Years
2%
CAGR 10-Years
4%
Gilead Sciences Inc
NASDAQ:GILD
Income from Continuing Operations
$456m
CAGR 3-Years
19%
CAGR 5-Years
-40%
CAGR 10-Years
-21%
Amgen Inc
NASDAQ:AMGN
Income from Continuing Operations
$3.8B
CAGR 3-Years
-19%
CAGR 5-Years
-14%
CAGR 10-Years
-2%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Income from Continuing Operations
$4B
CAGR 3-Years
13%
CAGR 5-Years
48%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Income from Continuing Operations
$3.9B
CAGR 3-Years
-1%
CAGR 5-Years
10%
CAGR 10-Years
26%

See Also

What is Iovance Biotherapeutics Inc's Income from Continuing Operations?
Income from Continuing Operations
-449.6m USD

Based on the financial report for Mar 31, 2024, Iovance Biotherapeutics Inc's Income from Continuing Operations amounts to -449.6m USD.

What is Iovance Biotherapeutics Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
-33%

Over the last year, the Income from Continuing Operations growth was -9%. The average annual Income from Continuing Operations growth rates for Iovance Biotherapeutics Inc have been -19% over the past three years , -27% over the past five years , and -33% over the past ten years .